Vasculitis Treatment Market By Drug Class (Biologics, Corticosteroids and Immunosuppressant), By Disease Condition (Large Vessel Vasculitis, Medium Vessel Vasculitis and Small Vessel Vasculitis) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

The vasculitis treatment market expected to reach US$ 601.2 Mn by 2026 from US$ 365.1 Mn in 2017 and projected to exhibit a steady compound annual growth rate (CAGR) of 5.7% during the forecast period from 2018 to 2026. According to Vasculitis Foundation 2016 report, the global prevalence of vasculitis is 1-9 per 100,000 people. Vasculitis shows high degree of incidence in the Caucasian population and is widely prevalent in the Scandinavian countries. Earlier cyclophosphamide was considered as the first line of treatment for all types of vasculitis. In 2010, United States Food and Drug Administration (USFDA) had approved rituximab for the treatment of vasculitis along with prednisolone. Pharmaceutical and biotechnology industries are constantly striving to achieve a targeted drug therapy approach for the treatment of vasculitis majorly focusing on monoclonal antibodies such as tocilizumab, mepolizumab and infliximab. CCX168 developed by ChemoCentryx, currently under phase II clinical trials is an immunosuppressant is projected to enter the market by 2021 and anticipated to register impressive growth during the forecast period for the treatment of ANCA associated vasculitis. In 2017, North America held the largest market share in the vasculitis treatment market on account of the developed healthcare infrastructure, increasing public health awareness resulting in early vasculitis diagnosis. North America is domicile to key players engaged in the treatment of vasculitis disease, contributes towards dominance of North America in this market. Asia Pacific will register significant growth during the forecast period owing to huge geriatric population suffering with large vessel vasculitis, and supportive regulatory environment for the treatment of vasculitis disease.

Market Synopsis

Vasculitis Treatment Market


Better Clinical Outcomes in Vasculitis Treatment Will Contribute To the Biologics Segment Growth

Currently biologics are leading the market by drug class segment and will continue to showcase excellent growth during the forecast period. In 2010, USFDA gave approval to rituximab for the treatment of vasculitis disease in combination with prednisolone. The dosage regimen currently postulated for rituximab throughout the globe is 4+2 protocol. In 2017, Biologics comprised of 38.98% share in the drug class segment on account of better drug safety & efficacy and rising prevalence of antineutrophil cytoplasmic autoantibodies (ANCA) associated renal vasculitis in elderly population. The only limitation of using rituximab therapy is its high cost, which hinders treatment in poor nations. Cyclophosphamide are used in patients showing resistance to rituximab therapy and its relatively low treatment cost contributes to its market growth in developing nations.

Vasculitis Treatment Market

Get a sample copy for more information

Accurate Diagnosis of Small Vessel Vasculitis to Record Highest Double Digit CAGR during the Forecast Period

The challenge that usually occur during the diagnosis of vasculitis is its overlapping symptoms with other inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, etc. The ambiguity occurs due to non-specificity of serological markers and irrational tissue biopsy. The chief inflammatory mediator that occurs in the vasculitis disease onset is leucocytes. The factors responsible for the accurate diagnosis of vasculitis is the technological advancement in the diagnostic kits and availability of skilled workforce to perform the diagnosis. In 2017, large vessel vasculitis occupied 45% share in the overall vasculitis disease epidemiology. The key attributes favoring the dominance of large vessel vasculitis are the rising prevalence of immunocompromised patients and medicines related adverse events encountered in the Caucasian populations. Small vessel vasculitis will be showcasing impressive growth during the forecast period owing to the increasing number of blood vessel aneurysm cases encountered in the Mongolian population and rampant growth in the reported cases of small vessel vasculitis initiated due to pesticide and chemical exposure.

Vasculitis Treatment Market

Get a sample copy for more information

Increasing public health awareness in Asia Pacific to set the stage for swift growth during the forecast period

In 2017, North America occupied 35.96% of the global market share for vasculitis treatment. The key factors responsible for the North America market growth are rising prevalence of large vessel vasculitis, presence of key players such as Bristol Myers Squibb Company, Celgene Corporation etc., and existence of advanced healthcare facilities. Asia Pacific will be the fastest growing market on account of large geriatric population suffering with small vessel vasculitis, enhanced funding by the pharmaceutical companies in the R&D segment and rising public health awareness resulting in early diagnosis and treatment.

Vasculitis Treatment Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Vasculitis treatment market report furnishes quantitative analysis along with its latest market trends. The market is segmented by drug class, by disease condition and geography.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Billion
Segmentation

 By Drug Class (2016–2026; US$ Mn)
 • Biologics
   o Rituximab
   o Infliximab
   o Adalimumab
 • Corticosteroids
   o Prednisone
   o Methylpredisolone
 • Immunosuppressant
 • Pipeline Analysis (Phase I and Phase II)

 By Disease Condition (2016–2026; US$ Mn)
 • Large Vessel Vasculitis
 • Medium Vessel Vasculitis
 • Small Vessel Vasculitis

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

Market assessment is performed in order to understand the prevailing market trends in the vasculitis treatment market. Market estimation is done by providing the compounded annual growth rate (CAGR) and data forecast for 2018-2026. Product portfolio is helpful in giving information of the FDA approved drugs currently prescribed for the treatment of vasculitis disease. Strategic collaboration, merger and acquisition among the key players for developing impressive product pipeline are mentioned in the business strategy section. The key players currently engaged in the Vasculitis Treatment market are F.Hoffman La-Roche Ltd., AstraZeneca, Baxter International, Bristol Myers Squibb Company, Celgene Corporation, ChemoCentryx, Daiichi Sankyo, Eli Lilly & Company, GlaxosmithKline Plc, Merck & Co., and Novartis AG.

Key questions answered in this report

  • How the global vasculitis treatment market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the vasculitis treatment market and valuable opportunities for the key players?
  • Who is the leading player in the global vasculitis treatment market?
  • Which is the leading and fastest region in the global vasculitis treatment market?
  • What are the diagnosis methods employed for the confirmation of vasculitis disease?
  • Currently what are the treatment guidelines used for the management and treatment of vasculitis disease?
  • What impact would the pipeline drugs have on the global vasculitis treatment market?
  • What are drivers and restrains governing the global vasculitis treatment market?
Choose License Type
Published Date:  May 2018
Category:  Pharmaceuticals
Report ID:   59143
Report Format:   PDF
Pages:   120
Rating:    4.2 (40)
Connect With Us
+1-408-641-3282
24/7 Research Support